Patel V - Search Results

1

Economic Burden of Comorbidities in Patients with Psoriasis in the USA.

Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Wu JJ, et al. Among authors: patel v. Dermatol Ther (Heidelb). 2023 Jan;13(1):207-219. doi: 10.1007/s13555-022-00832-9. Epub 2022 Nov 19. Dermatol Ther (Heidelb). 2023. PMID: 36402940 Free PMC article.

2

Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.

Armstrong A, Xia Q, John AR, Patel V, Seigel L. Armstrong A, et al. Among authors: patel v. Dermatol Ther (Heidelb). 2022 Sep;12(9):2087-2103. doi: 10.1007/s13555-022-00775-1. Epub 2022 Aug 10. Dermatol Ther (Heidelb). 2022. PMID: 35947341 Free PMC article.

3

Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.

Wu JJ, Wang CA, Jobson G, Davidson D, Kalirai S, Zhu J, Suryavanshi M, Mittal M, Patel V, Seigel L. Wu JJ, et al. Among authors: patel v. J Dermatolog Treat. 2023 Dec;34(1):2177095. doi: 10.1080/09546634.2023.2177095. J Dermatolog Treat. 2023. PMID: 36736349 Free article.

4

Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.

Schmidt L, Wang CA, Patel V, Davidson D, Kalirai S, Panda A, Seigel L. Schmidt L, et al. Among authors: patel v. Dermatol Ther (Heidelb). 2023 Sep;13(9):2019-2030. doi: 10.1007/s13555-023-00975-3. Epub 2023 Jul 30. Dermatol Ther (Heidelb). 2023. PMID: 37517029 Free PMC article.

5

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.

Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, Chirikov V. Armstrong AW, et al. Among authors: patel v. Dermatol Ther (Heidelb). 2023 Nov;13(11):2589-2603. doi: 10.1007/s13555-023-00977-1. Epub 2023 Jul 31. Dermatol Ther (Heidelb). 2023. PMID: 37525000 Free PMC article.

6

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.

Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, Chirikov V. Armstrong AW, et al. Among authors: patel v. Dermatol Ther (Heidelb). 2023 Nov;13(11):2605-2607. doi: 10.1007/s13555-023-01043-6. Dermatol Ther (Heidelb). 2023. PMID: 37853229 Free PMC article. No abstract available.

7

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.

Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Armstrong AW, et al. Among authors: patel v, patel d. Dermatol Ther (Heidelb). 2024 Feb;14(2):421-439. doi: 10.1007/s13555-023-01089-6. Epub 2024 Jan 22. Dermatol Ther (Heidelb). 2024. PMID: 38252376 Free PMC article.

8

Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey.

Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, Wolin D, Boyle K, Seigel L. Bhutani T, et al. Among authors: patel v. J Dermatolog Treat. 2024 Dec;35(1):2366532. doi: 10.1080/09546634.2024.2366532. Epub 2024 Jun 24. J Dermatolog Treat. 2024. PMID: 38914422 Free article.

9

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Armstrong AW, et al. Among authors: patel v. Dermatol Ther (Heidelb). 2024 Jul;14(7):1891-1899. doi: 10.1007/s13555-024-01201-4. Epub 2024 Jun 22. Dermatol Ther (Heidelb). 2024. PMID: 38907877 Free PMC article.

10

Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis.

van de Wetering G, Ignacio T, Dhanda D, Patel V, Zhang Y, Zhuo J. van de Wetering G, et al. Among authors: patel v. J Med Econ. 2022 Jan-Dec;25(1):421-427. doi: 10.1080/13696998.2022.2051912. J Med Econ. 2022. PMID: 35297738 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,116 results

Search Page

Filters